Wainberg, Z. A., Cutsem, E. V., Götze, T., Şendur, M. A. N., Al-Farhat, Y., Wysocki, P. J., Mansoor, W., Bitzer, M., Skoropad, V., Rey, F., Oh, D., Liberman, M., Molena, D., Muro, K., Hyung, W. J., Cheng, L., Hernandorena, F., Robbins, S., Janjigian, Y. Y., Tabernero, J. (2026). Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4070